Because of the significant contribution of the PI3K/AKT signaling pathway to breast cancer progression, Pan-PI3K drugs targeting the four isoforms of class I PI3K were developed but showed significant toxicity [12]. The gene discussed is AKT1; the disease is breast carcinoma.